Skip to Content

Discontinuation of Development of TAK-242 for Severe Sepsis

OSAKA, Japan, February 20, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced the discontinuation of clinical development for its investigational compound TAK-242,   a treatment for severe sepsis.

A Phase 3 clinical study of the compound was being conducted in Japan, the U.S. and Europe. However, following a thorough review of development strategy, Takeda has concluded that TAK-242’s profile does not meet the criteria to support continuation of further development activities. This decision has not been influenced by any concerns over the safety or efficacy of the compound.

In the U.S., Takeda recently received FDA marketing approval for both KAPIDEX in the treatment of GERD (January) and ULORIC in the treatment of chronic management of hyperuricemia in patients with gout (February). The company will continue to enhance its established R&D pipeline through a mix of accelerating development projects in all core therapeutic areas; in-house R&D activities; LCM (Life Cycle Management); in-licensing and alliances activities.

Posted: February 2009